Shares of BioSyent Inc. (CVE:RX - Get Free Report) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$10.86 and traded as high as C$11.26. BioSyent shares last traded at C$11.25, with a volume of 2,351 shares.
BioSyent Trading Down 3.9 %
The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19. The company has a market cap of C$125.29 million, a P/E ratio of 18.02 and a beta of 0.93. The business has a fifty day moving average price of C$10.88 and a 200-day moving average price of C$9.95.
BioSyent (CVE:RX - Get Free Report) last issued its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, meeting the consensus estimate of C$0.13. The business had revenue of C$8.95 million during the quarter, compared to analysts' expectations of C$8.80 million. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. On average, analysts forecast that BioSyent Inc. will post 0.6944444 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Seyed Ahmad Ashrafi sold 2,320 shares of BioSyent stock in a transaction on Friday, September 20th. The shares were sold at an average price of C$10.95, for a total value of C$25,404.00. 33.65% of the stock is owned by insiders.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Stories
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
